InvestorsHub Logo
Followers 0
Posts 73
Boards Moderated 0
Alias Born 05/03/2008

Re: None

Tuesday, 08/18/2020 7:21:44 PM

Tuesday, August 18, 2020 7:21:44 PM

Post# of 8431
Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of unusually large options trading activity on Monday. Stock investors purchased 4,890 put options on the stock. This is an increase of approximately 4,513% compared to the typical daily volume of 106 put options.

In other Halozyme Therapeutics news, Director James M. Daly sold 34,337 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $29.12, for a total value of $999,893.44. Following the completion of the transaction, the director now owns 31,365 shares in the company, valued at $913,348.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 12,000 shares of the company’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $29.01, for a total value of $348,120.00. Following the sale, the senior vice president now directly owns 182,800 shares in the company, valued at approximately $5,303,028. The disclosure for this sale can be found here. Insiders have sold 67,724 shares of company stock worth $1,857,024 in the last three months. Corporate insiders own 2.60% of the company’s stock.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News